<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00002127</url>
  </required_header>
  <id_info>
    <org_study_id>230A</org_study_id>
    <secondary_id>W-001</secondary_id>
    <nct_id>NCT00002127</nct_id>
  </id_info>
  <brief_title>A Phase II, Parallel Group, Randomized, Placebo-Controlled Study of the Safety and Efficacy of Thalidomide in Reducing Weight Loss in Adults With HIV Wasting Syndrome</brief_title>
  <official_title>A Phase II, Parallel Group, Randomized, Placebo-Controlled Study of the Safety and Efficacy of Thalidomide in Reducing Weight Loss in Adults With HIV Wasting Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Celgene Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NIH AIDS Clinical Trials Information Service</source>
  <brief_summary>
    <textblock>
      To evaluate the safety, antiviral and anti-TNF-alpha activity, and preliminary efficacy of&#xD;
      thalidomide in reducing weight loss in patients with HIV wasting syndrome.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients are randomized to receive either thalidomide at 1 of 2 doses or placebo for 8 weeks.&#xD;
      Patients who respond may continue in double-blinded treatment for an additional 4 weeks;&#xD;
      nonresponding patients may receive thalidomide for up to 4 weeks. Per amendment, patients may&#xD;
      receive thalidomide for more than 12 weeks on a compassionate basis.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <enrollment>75</enrollment>
  <condition>HIV Infections</condition>
  <condition>HIV Wasting Syndrome</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Thalidomide</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
        Concurrent Medication:&#xD;
&#xD;
        Allowed:&#xD;
&#xD;
          -  Primary prophylaxis for opportunistic infections (if AFB blood culture negative).&#xD;
&#xD;
          -  Chronic suppressive therapy (maintenance) for opportunistic infections OTHER THAN&#xD;
             Mycobacterium avium Complex (MAC).&#xD;
&#xD;
        Patients must have:&#xD;
&#xD;
          -  Documented HIV infection.&#xD;
&#xD;
          -  Wasting syndrome.&#xD;
&#xD;
          -  Negative blood PCR for acid-fast bacteria (AFB) or a negative AFB blood culture within&#xD;
             48 days prior to study entry.&#xD;
&#xD;
          -  No active opportunistic infection requiring systemic therapy within 6 weeks prior to&#xD;
             study entry.&#xD;
&#xD;
          -  Life expectancy of at least 6 weeks.&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
        Co-existing Condition:&#xD;
&#xD;
        Patients with the following symptoms or conditions are excluded:&#xD;
&#xD;
          -  Chronic diarrhea (five or more unformed stools per day).&#xD;
&#xD;
          -  Peripheral neuropathy of grade 2 or worse.&#xD;
&#xD;
          -  Requirement for tube feeding or intravenous feeding.&#xD;
&#xD;
          -  Any disorder associated with moderate to severe edema (e.g., cirrhosis, nephrosis,&#xD;
             congestive heart failure).&#xD;
&#xD;
          -  Inability to ingest at least a maintenance diet based on present weight.&#xD;
&#xD;
          -  Any condition that precludes study participation.&#xD;
&#xD;
          -  Not under the care of a primary physician.&#xD;
&#xD;
        Concurrent Medication:&#xD;
&#xD;
        Excluded:&#xD;
&#xD;
          -  Chronic suppressive therapy (maintenance) or secondary prophylaxis for Mycobacterium&#xD;
             avium Complex (MAC) (suppressive therapy for other opportunistic infections is&#xD;
             allowed).&#xD;
&#xD;
        Concurrent Treatment:&#xD;
&#xD;
        Excluded:&#xD;
&#xD;
          -  Radiotherapy.&#xD;
&#xD;
        Patients with the following prior conditions are excluded:&#xD;
&#xD;
          -  Any neoplasms other than non-medicated (i.e., not receiving systemic or intralesional&#xD;
             chemotherapy) Kaposi's sarcoma within 1 month prior to study entry.&#xD;
&#xD;
          -  Prior intolerance to thalidomide.&#xD;
&#xD;
        Prior Medication:&#xD;
&#xD;
        Excluded:&#xD;
&#xD;
          -  ddC within 1 month prior to study entry.&#xD;
&#xD;
          -  Acute systemic therapy for opportunistic infections within 6 weeks prior to study&#xD;
             entry.&#xD;
&#xD;
          -  Agents that are anabolic, catabolic, or immunomodulatory (including interferons,&#xD;
             megestrol, dronabinol, oxandrolone, growth hormone, systemic corticosteroids, and&#xD;
             pentoxifylline) within 30 days prior to study entry.&#xD;
&#xD;
        Prior Treatment:&#xD;
&#xD;
        Excluded:&#xD;
&#xD;
          -  Radiotherapy within 6 weeks prior to study entry.&#xD;
&#xD;
        Required ONLY IF patient is on antiretroviral therapy:&#xD;
&#xD;
          -  Stable regimen of AZT or ddI for at least 1 month prior to study entry. Active drug&#xD;
             abuse within 3 months prior to study entry.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Marin County Specialty Clinic</name>
      <address>
        <city>Greenbrae</city>
        <state>California</state>
        <zip>94904</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AIDS Community Research Consortium</name>
      <address>
        <city>Redwood City</city>
        <state>California</state>
        <zip>940631633</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCSD Med Ctr - Owen Clinic</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>921038681</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>San Francisco Gen Hosp</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaiser Permanente Med Ctr</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gottlieb Med Group</name>
      <address>
        <city>Sherman Oaks</city>
        <state>California</state>
        <zip>91403</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>George Washington Univ Med Ctr</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20037</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Community Research Initiative of South Florida</name>
      <address>
        <city>Coral Gables</city>
        <state>Florida</state>
        <zip>33146</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kansas City AIDS Research Consortium</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Michael's Med Ctr</name>
      <address>
        <city>Newark</city>
        <state>New Jersey</state>
        <zip>07102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rockefeller Univ</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Thomas Jefferson Med College</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Advanced Research Management</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>981225314</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Stirling D, Sherman M, Strauss S. Thalidomide. A surprising recovery. J Am Pharm Assoc (Wash). 1997 May-Jun;NS37(3):306-13.</citation>
    <PMID>9170807</PMID>
  </reference>
  <verification_date>July 1997</verification_date>
  <study_first_submitted>November 2, 1999</study_first_submitted>
  <study_first_submitted_qc>August 30, 2001</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 31, 2001</study_first_posted>
  <last_update_submitted>June 23, 2005</last_update_submitted>
  <last_update_submitted_qc>June 23, 2005</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 24, 2005</last_update_posted>
  <keyword>Acquired Immunodeficiency Syndrome</keyword>
  <keyword>Cachexia</keyword>
  <keyword>Thalidomide</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Wasting Syndrome</mesh_term>
    <mesh_term>Wasting Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Weight Loss</mesh_term>
    <mesh_term>Cachexia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thalidomide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

